A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

NCT00849680 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1
HIV Infections

Interventions

OTHER: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
BIOLOGICAL: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
BIOLOGICAL: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
BIOLOGICAL: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine

Sponsor

Merck Sharp & Dohme LLC